| AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial PA LeWitt, AR Rezai, MA Leehey, SG Ojemann, AW Flaherty, ... The Lancet Neurology 10 (4), 309-319, 2011 | 767 | 2011 |
| The Parkinson's progression markers initiative (PPMI)–establishing a PD biomarker cohort K Marek, S Chowdhury, A Siderowf, S Lasch, CS Coffey, ... Annals of clinical and translational neurology 5 (12), 1460-1477, 2018 | 450 | 2018 |
| Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis CC Tang, KL Poston, T Eckert, A Feigin, S Frucht, M Gudesblatt, ... The Lancet Neurology 9 (2), 149-158, 2010 | 397 | 2010 |
| Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study A Siderowf, L Concha-Marambio, DE Lafontant, CM Farris, Y Ma, ... The Lancet Neurology 22 (5), 407-417, 2023 | 304 | 2023 |
| Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: a double‐blind, randomized, controlled trial C Warren Olanow, RT Bartus, TL Baumann, S Factor, N Boulis, M Stacy, ... Annals of neurology 78 (2), 248-257, 2015 | 279 | 2015 |
| Ultra–Low-Dose 18F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs KT Chen, E Gong, FB de Carvalho Macruz, J Xu, A Boumis, M Khalighi, ... Radiology 290 (3), 649-656, 2019 | 260 | 2019 |
| Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease CC Tang, KL Poston, V Dhawan, D Eidelberg Journal of Neuroscience 30 (3), 1049-1056, 2010 | 222 | 2010 |
| Multimodal deep learning for Alzheimer’s disease dementia assessment S Qiu, MI Miller, PS Joshi, JC Lee, C Xue, Y Ni, Y Wang, I De Anda-Duran, ... Nature communications 13 (1), 3404, 2022 | 185 | 2022 |
| Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort T Simuni, A Siderowf, S Lasch, CS Coffey, C Caspell‐Garcia, D Jennings, ... Movement Disorders 33 (5), 771-782, 2018 | 175 | 2018 |
| A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research T Simuni, LM Chahine, K Poston, M Brumm, T Buracchio, M Campbell, ... The Lancet Neurology 23 (2), 178-190, 2024 | 162 | 2024 |
| Association of short and long sleep duration with amyloid-β burden and cognition in aging JR Winer, KD Deters, G Kennedy, M Jin, A Goldstein-Piekarski, KL Poston, ... JAMA neurology 78 (10), 1187-1196, 2021 | 162 | 2021 |
| Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease B Cholerton, CO Johnson, B Fish, JF Quinn, KA Chung, ... Parkinsonism & related disorders 50, 29-36, 2018 | 146 | 2018 |
| CD4+ T cells contribute to neurodegeneration in Lewy body dementia D Gate, E Tapp, O Leventhal, M Shahid, TJ Nonninger, AC Yang, ... Science 374 (6569), 868-874, 2021 | 133 | 2021 |
| A disease-specific metabolic brain network associated with corticobasal degeneration M Niethammer, CC Tang, A Feigin, PJ Allen, L Heinen, S Hellwig, ... Brain 137 (11), 3036-3046, 2014 | 133 | 2014 |
| Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson’s disease S Sundaram, RL Hughes, E Peterson, EM Müller-Oehring, ... Neuroscience & Biobehavioral Reviews 103, 305-315, 2019 | 123 | 2019 |
| Episodic recognition memory and the hippocampus in Parkinson's disease: a review T Das, JJ Hwang, KL Poston Cortex 113, 191-209, 2019 | 121 | 2019 |
| Functional brain networks and abnormal connectivity in the movement disorders KL Poston, D Eidelberg Neuroimage 62 (4), 2261-2270, 2012 | 121 | 2012 |
| Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross … T Simuni, L Uribe, HR Cho, C Caspell-Garcia, CS Coffey, A Siderowf, ... The Lancet Neurology 19 (1), 71-80, 2020 | 115 | 2020 |
| High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis A Sturchio, AK Dwivedi, CB Young, T Malm, L Marsili, JS Sharma, ... EClinicalMedicine 38, 2021 | 108 | 2021 |
| Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease M Niethammer, CC Tang, PA LeWitt, AR Rezai, MA Leehey, SG Ojemann, ... JCI insight 2 (7), 2017 | 102 | 2017 |